A Database Survey to Evaluate the Safety of Immune Globulin Subcutaneous (Human), 20% Solution in Participants With Primary Immunodeficiency

Inclusion Criteria

• •1. Patients with primary immunodeficiency (PID) enrolled in the PID patient registry.
• •2. Participant for whom study drug is entered in the therapeutic drug field on the data set.
• •3. Participant who is entered the intractable disease diagnosis corresponding to PID in the intractable disease information field.
• •4. Participant for whom the presence or absence of adverse events has been entered in the column of adverse events.